Health technology agency insights: informing modification of a qualitative benefit risk framework for health technology reassessment of prescription medications

16 September 2019 - This study's intent was to determine if a qualitative benefit risk framework could be used or modified ...

Read more →

NICE recommends Takhzyro

18 September 2019 - NICE - a health technology appraisal body in England and Wales - has recommended the use ...

Read more →

HTA in the European Union: osteoporosis screening without proof of benefit

16 September 2019 - For the first time, an IQWiG team is in charge of assessing health technology for the ...

Read more →

Lenvima to get benefit as first-line treatment of hepatocellular carcinoma

16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...

Read more →

EMA publishes agenda for 16-19 CHMP meeting

13 September 2019 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

Defining capacity building in the context of HTA: a proposal by the HTAi Scientific Development and Capacity Building Committee

11 September 2019 - A review of capacity building activities undertaken by HTAi members, members of the International Network of Agencies ...

Read more →

ICER publishes evidence report on additive cardiovascular disease therapies

12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...

Read more →

SMC U-turn for Vertex’s CF drugs

12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients ...

Read more →

NICE publishes its 600th technology appraisal guidance

12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the ...

Read more →

ICER releases draft evidence report on diabetes therapies

11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...

Read more →

ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate

10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...

Read more →

As value assessment frameworks evolve, are they finally ready for prime time?

9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...

Read more →

SMC - September 2019 decisions

9 September 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States

5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...

Read more →

ICER to assess treatments for cystic fibrosis

6 September 2019 - Report will be subject of California Technology Assessment Forum meeting in April 2020; open Input now being ...

Read more →